AMRX - Company ID 0001723128
Amneal Pharmaceuticals, Inc. trades as AMRX and has a market capitalization of $5.36 B, making it the #1368 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $3.02B, up 8.0% from the prior year and net income of $72.06M. This page tracks Amneal Pharmaceuticals, Inc. through 664 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years Amneal Pharmaceuticals, Inc.'s revenue grew from $1.02B to $3.02B, a compound annual growth rate of 12.8%. Net profit margin expanded from 0.0% to 2.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-12 |
| Insider sale notice | 144 | 2026-05-11 |
| Insider trade | 4 | 2026-05-08 |
| Insider trade | 4 | 2026-05-08 |
| Insider trade | 4 | 2026-05-08 |
| Insider trade | 4 | 2026-05-08 |
| Insider trade | 4 | 2026-05-08 |
| Insider trade | 4 | 2026-05-08 |
Amneal Pharmaceuticals, Inc. - Amneal Reports First Quarter 2026 Financial Results
Amneal Pharmaceuticals, Inc. - Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
Amneal Pharmaceuticals, Inc. - Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%
Amneal Pharmaceuticals, Inc. - Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month
A founder-led culture of redefining what's possible
The largest companies sharing Amneal Pharmaceuticals, Inc.'s SEC industry classification (pharmaceutical preparations).
Amneal Pharmaceuticals, Inc. (AMRX) has a market capitalization of $5.36 B as of 2026-07-09, ranking #1368 among US-listed companies.
Amneal Pharmaceuticals, Inc. reported revenue of $3.02B for fiscal year 2025, an increase of 8.0% year over year.
Yes. Amneal Pharmaceuticals, Inc. reported net income of $72.06M in its latest fiscal year.